RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older

• DOI: 10.1001/jama.2024.15775
• Publication Date: 2024-09-04T15:06:39Z
• Authors: Diya Surie; Wesley H. Self; Yuwei Zhu; Katharine A. Yuen...; Cassandra A. Johnson; Carlos G. Grijalva; Fatimah S. Dawood; ; Manjusha Gaglani; Shekhar Ghamande; Tresa McNeal; Cristie Columbus; Robert L. Gottlieb; Jay S. Steingrub; Jennifer DeCuir; Meredith L. McMorrow; Sascha Ellington; Nathaniel M. Lewis; Abhijit Duggal; Laurence W. Busse; William S. Bender; Matthew E. Prekker; Anne Frosch; Ithan D. Peltan; Samuel M. Brown; David N. Hager; Michelle N. Gong; Amira Mohamed; Akram Khan; Catherine L. Hough; Jennifer G. Wilson; Jarrod M. Mosier; Nida Qadir; Steven Y. Chang; Adit A. Ginde; Nicholas M. Mohr; Anne Zepeski; Christopher Mallow; Adam S. Lauring; Emily T. Martin; Aleda M. Leis; Estelle S. Harris; Nicholas J. Johnson; Vasisht Srinivasan; H. Keipp Talbot; Natasha Halasa; James D. Chappell; Kelsey N. Womack; Jillian P. Rhoads; Adrienne Baughman; Sydney A. Swan; Todd W. Rice; Jonathan D. Casey; Paul W. Blair; Kevin W. Gibbs; Jennie H. Kwon; Bijal Parikh; Ivana A. Vaughn; Mayur Ramesh; Basmah Safdar
• Keywords: Respiratory illness

This study evaluates the effectiveness of respiratory syncytial virus vaccine against hospitalization for acute illness among US adults aged 60 years and older.